271 related articles for article (PubMed ID: 24083743)
1. Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals.
Cihan YB; Arslan A; Ergul MA
Asian Pac J Cancer Prev; 2013; 14(8):4779-83. PubMed ID: 24083743
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
3. Roles of white blood cells and subtypes as inflammatory markers in skin cancer.
Baykan H; Cihan YB; Ozyurt K
Asian Pac J Cancer Prev; 2015; 16(6):2303-6. PubMed ID: 25824754
[TBL] [Abstract][Full Text] [Related]
4. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
7. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
[TBL] [Abstract][Full Text] [Related]
8. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
9. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
10. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Prostate-Specific Antigen-Related Indexes, Neutrophil-to-Lymphocyte Ratio in Patients with Concurrent Benign Prostatic Hyperplasia and Histologic Prostatitis.
Wang F; Ge A; Dai A; Wang Z; Mo Z
Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013341
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value.
Ceylan Y; Günlüsoy B; Degirmenci T; Bolat D; Kozacioglu Z; Vardar E; Topçu YK; Polat S
Arch Esp Urol; 2016 Nov; 69(9):627-635. PubMed ID: 27845694
[TBL] [Abstract][Full Text] [Related]
14. Effect of prostatic massage on serum complexed prostate-specific antigen levels.
Tarhan F; Orçun A; Küçükercan I; Camursoy N; Kuyumcuoğlu U
Urology; 2005 Dec; 66(6):1234-8. PubMed ID: 16360449
[TBL] [Abstract][Full Text] [Related]
15. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
Froschermaier SE; Pilarsky CP; Wirth MP
Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
[TBL] [Abstract][Full Text] [Related]
18. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
[TBL] [Abstract][Full Text] [Related]
20. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
